65G.F NEXTCELL PHARMA AB

Healthcare Biotechnology Frankfurt Exchange
0.0082 EUR
Close of Nov 11, 2026
0.0059 0.1674
Market cap
EUR 1.04M
P/E
-
P/B
0.19x
ROE
-
Dividend yield
-
Fundamental score
-

Is 65G.F undervalued?

Graham number

The Graham number of NEXTCELL PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NEXTCELL PHARMA AB fundamental analysis

No fundamental analysis for NEXTCELL PHARMA AB yet.

NEXTCELL PHARMA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NEXTCELL PHARMA AB

NextCell Pharma AB (publ), a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The compa…

Full company profile